Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option. Net proceeds are expected to be...
By Len Zehr Arun Menawat, CEO With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on...
By Len Zehr After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European...
By Len Zehr After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX...